生产企业：TREOS Bio
PolyPEPI-1018 is TREOS Bio's lead off-the-shelf multi-peptide immunotherapy candidate, developed using proprietary Promiscuous EPItopes (PEPI) Technology. It has been tested in three phase I/II clinical trials. The off-the-shelf design targets shared, non-mutated tumor antigens rather than patient-specific neoantigens, offering potential advantages in simpler logistics, faster treatment availability, and broader scalability compared to fully individualized approaches. TREOS Bio is now preparing to advance PolyPEPI1018 through Phase 2B clinical development in microsatellite-stable metastatic colorectal cancer (MSS mCRC).
PolyPEPI-1018 is TREOS Bio's lead off-the-shelf multi-peptide immunotherapy candidate, developed using proprietary Promiscuous EPItopes (PEPI) Technology. It has been tested in three phase I/II clinical trials. The off-the-shelf design targets shared, non-mutated tumor antigens rather than patient-specific neoantigens, offering potential advantages in simpler logistics, faster treatment availability, and broader scalability compared to fully individualized approaches. TREOS Bio is now preparing to advance PolyPEPI1018 through Phase 2B clinical development in microsatellite-stable metastatic colorectal cancer (MSS mCRC).
